- Home
- ESPR vs LAAC Comparison
ESPR vs LAAC Comparison
Compare ESPR & LAAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- LAAC
- Stock Information
- Founded
- ESPR 2008
- LAAC 2007
- Country
- ESPR United States
- LAAC Canada
- Employees
- ESPR N/A
- LAAC N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- LAAC
- Sector
- ESPR Health Care
- LAAC
- Exchange
- ESPR Nasdaq
- LAAC Nasdaq
- Market Cap
- ESPR 399.0M
- LAAC 542.4M
- IPO Year
- ESPR 2013
- LAAC N/A
- Fundamental
- Price
- ESPR $2.30
- LAAC $2.79
- Analyst Decision
- ESPR Buy
- LAAC Hold
- Analyst Count
- ESPR 5
- LAAC 3
- Target Price
- ESPR $7.30
- LAAC $5.58
- AVG Volume (30 Days)
- ESPR 8.8M
- LAAC 1.3M
- Earning Date
- ESPR 11-07-2024
- LAAC 11-05-2024
- Dividend Yield
- ESPR N/A
- LAAC N/A
- EPS Growth
- ESPR N/A
- LAAC 3133.17
- EPS
- ESPR N/A
- LAAC 7.78
- Revenue
- ESPR $295,451,000.00
- LAAC N/A
- Revenue This Year
- ESPR $186.90
- LAAC N/A
- Revenue Next Year
- ESPR $31.10
- LAAC $208.49
- P/E Ratio
- ESPR N/A
- LAAC $0.36
- Revenue Growth
- ESPR 187.12
- LAAC N/A
- 52 Week Low
- ESPR $1.58
- LAAC $2.07
- 52 Week High
- ESPR $3.94
- LAAC $6.69
- Technical
- Relative Strength Index (RSI)
- ESPR 44.79
- LAAC 38.72
- Support Level
- ESPR $2.12
- LAAC $2.66
- Resistance Level
- ESPR $2.54
- LAAC $3.21
- Average True Range (ATR)
- ESPR 0.35
- LAAC 0.16
- MACD
- ESPR -0.10
- LAAC -0.04
- Stochastic Oscillator
- ESPR 21.90
- LAAC 18.06
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About LAAC Lithium Americas (Argentina) Corp.
Lithium Argentina is a pure-play lithium producer. The company owns two neighboring lithium brine resources in northwest Argentina: Cauchari-Olaroz and Pastos Grandes. Cauchari-Olaroz entered production in 2023, while Pastos Grandes is still in development. Lithium Argentina plans for both resources to be fully integrated with onside downstream processing capabilities and will sell into the lithium chemical market.